The dark side of glucose

[1]  C. Colaco,et al.  A glycation connection , 1994, Nature.

[2]  P. Libby,et al.  An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  R. Bucala,et al.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[5]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[6]  G. Williams,et al.  Study of the rat adrenal renin-angiotensin system at a cellular level. , 1995, The Journal of clinical investigation.

[7]  J. Loike,et al.  Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. , 1994, The Journal of biological chemistry.

[8]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[9]  J. Williamson,et al.  Glucose and diabetic vascular disease 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  K. Federlin,et al.  Impairment of Polymorphonuclear Leukocyte Function and Metabolic Control of Diabetes , 1992, Diabetes Care.

[11]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[12]  N. Taniguchi,et al.  beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. , 1993, The Journal of clinical investigation.

[13]  A. Schmidt,et al.  Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.

[14]  T. Koschinsky,et al.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Simionescu,et al.  The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. , 1994, The Journal of biological chemistry.

[16]  J. Zweier,et al.  Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide , 1995, Nature Medicine.

[17]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[18]  S. Ogawa,et al.  Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Perry,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.